Merck Sharp & Dohme Pty Ltd—Vioxx (Rofecoxib) Tablets and Oral Suspension, All batches

What are the defects?

The company has decided to recall Vioxx based on new information from a recent clinical study which showed that there was an increased risk of cardiovascular events such as heart attack and stroke beginning after 18 months of treatment.

What are the hazards?

Increased risk of cardiovascular and cerebrovascular disease. (Heart Attack and Stroke).

What should consumers do?

Consumers to call the Merck Sharp & Dohme Customer Service Line on 1800 066 426.

Supplier
Merck Sharp & Dohme Pty Ltd
Where the product was sold
Nationally

Responsible regulator

Therapeutic Goods Administration is the responsible regulator for this recall.

Product category